Latest Allergan Inc (AGN) Headlines
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 3:03PM CDT
It appears that not even geopolitical concerns and threats of a global growth slowdown can keep the broad-based S&P 500 from running to fresh all-time highs. For skeptics like me, that's an opportunity to see whether companies have earned their...
Survey Shows 3 out of 4 Women in the U.S. (ages 18-65) Think the Length, Thickness, or Color of Their Eyelashes is Inadequate(1)
PR Newswire - Thu Mar 13, 8:00AM CDT
According to a new U.S. survey conducted by Wakefield Research on behalf of Allergan, Inc., maker of BOTOX® Cosmetic (onabotulinumtoxinA), three out of four women (n = 500) have admitted to having concerns about their inadequate eyelashes. Of the women polled in the survey, 49 percent stated that they found the thickness or volume of their lashes inadequate.1 Additionally, 52 percent of women have noticed that their lashes have gotten thinner, shorter or lighter over time.1 And, 51 percent of those surveyed agreed that they either are using more mascara than they'd like, laying it on too thickly, or are afraid to have anyone see them without it.1
Beverly Hills Physicians is Proud to be Recognized with an Allergan Award
PR Newswire - Wed Mar 12, 7:25PM CDT
Throughout Southern California, Beverly Hills Physicians has long been the ideal option for cosmetic procedures like breast augmentation. With BHP's various facilities throughout the region (each approved by the American Association for Accreditation of Ambulatory Surgery, Inc.), their plastic surgery patients always know they're receiving the safest and most effective surgery. Further still, their experience, skill and dedication to cost-effective treatment means that every patient can achieve the same level of quality you'd expect to see among breast implants in Beverly Hills. That's why it is such a pleasure to announce that BHP was recently presented with the prestigious ALLERGAN PARTNER PRIVILEGES® (APP) Top 50 award - for the second year in a row!
Can Valeant Continue This Growth?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:00PM CDT
Canada's Valeant Pharmaceuticals is a good example of what can be done when a company chooses to go its own way and zig while others zag. In an industry that had becoming increasingly skittish about mergers and acquisitions as a growth driver,...
Equities Hitting New High: Allergan, Aetna, Ecolab, and BioDelivery Sciences Intl.
PR Newswire - Wed Mar 12, 11:17AM CDT
On Tuesday, March 11, 2014, the NASDAQ Composite finished at 4,307.19, down 0.63%. The Dow Jones Industrial Average closed the session at 16,351.25, down 0.41% and the S&P 500 ended the day at 1867.63, lower by 0.51%. The losses were broad based as nine out of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include Allergan Inc. (NYSE:AGN), Aetna Inc. (NYSE:AET), Ecolab Inc. (NYSE:ECL), and BioDelivery Sciences International Inc. (NASDAQ:BDSI). Free research on these four companies can be accessed at:
Kythera Regains ATX-101 from Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:39PM CDT
Kythera regained all rights to ATX-101 outside the U.S. and Canada from the HealthCare segment of Bayer.
Global Ophthalmic Drugs Market Report 2013-2018: Dry Eye, Anti-Glaucoma, Anti-Allergy/Inflammatory/Infective, Retinal Drugs
M2 - Mon Mar 10, 7:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w43p49/ophthalmic_drugs) has announced the addition of the "Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018" report to their offering. The global ophthalmic drugs market is rapidly growing due to increasing prevalence of eye disorders such as glaucoma, dry eye diseases and retinal diseases. Changing lifestyle, improved medical infrastructure, technological changes, increase in healthcare spending and aging population is also supporting the growth of the ophthalmic drugs market. Glaucoma is the largest drugs segment in global ophthalmic drugs market. Some of the major drugs for glaucoma treatment are Lumigan, Combigan, Xalatan, Ganfort and Saflutan. Diquas, Hyalein and Restasis are the major drugs for dry eye diseases. The retinal drugs market includes Ozurdex, Macugen, Visudyne and Lucentis. Patanol/Pataday, Tobradex, Vigamox and Bepreve are major ocular anti-inflammatory drugs. The ophthalmic drugs market covers prescription based drugs, OTC drugs and pipeline drugs. This report forecasts future potential of all these drug markets and analyses drivers and opportunities, restraints and challenges, market trends, Porter's forces, competitive landscape and company profiles of key players. The report categorizes the global ophthalmic drugs market based on major eye disorders, treatment drugs and geography. The treatment drugs market comprises treatment of major eye disorders such as glaucoma, dry eye drugs, retinal diseases and ocular inflammatory diseases. The market is further segmented on the basis of prescription based drugs, OTC drugs and pipeline drugs in different eye disorder areas. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Ophthalmic Drugs - Industry Analysis Chapter 4 Ophthalmic Drugs Market Trends Chapter 5 Porter's Five Force Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Ophthalmic Drugs Market - Treatment Drugs Chapter 8 Ophthalmic Drugs Market: Regional Analysis Chapter 9 Prescription vs. Over the Counter Drugs Chapter 10 Competitive Landscape Chapter 11 Company Profiles - Allergan - Merck - Novartis - Pfizer - Roche - Santen Pharmaceutical For more information visit http://www.researchandmarkets.com/research/w4...lmic_drugs
Allergan Up 39.3% Since SmarTrend Uptrend Call (AGN)
Comtex SmarTrend(R) - Fri Mar 07, 9:40AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on July 15th, 2013 at $91.28. In approximately 8 months, Allergan has returned 39.32% as of today's recent price of $127.17.
LatisseDoctor.com Reports on Allergan's Continued Work on Hair Loss Product Despite Delays
PRWeb - Fri Mar 07, 3:11AM CST
Allergan's move to take part in the massive hair loss market is the subject of the latest LatisseDoctor.com report. The current lineup of Allergan products include JUVÉDERM(R), BOTOX(R), VIVITE(R), SkinMedica(R), NATRELLE(R) breast implants and LATISSE(R). It is this last product that was the launching point for Allergan's attempt to enter the hair loss market reports LatisseDoctor.com. The active ingredient, bimatoprost was found to improve eyelash growth, and Allergan researchers are hoping it can do the same for hair.
Vansen Pharma Inc. appoints Ali Moghaddam to its Board of Advisors
PR Newswire - Thu Mar 06, 9:47AM CST
Vansen Pharma Inc. [OTCQB: VNSN] is pleased to announce the appointment of Mr. Ali Moghaddam to its Board of Advisors. Mr. Moghaddam is an accomplished pharmaceutical executive with over 25 years of experience in both Canada and the U.S., having played a transformational role with companies such as Bristol-Myers Squibb Canada, Linson Pharma Inc. (generic business unit of BMS), Allergan Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group). He brings a proven track record of hands-on leadership within the life sciences field, in the areas of Product Life Cycle Management, Sales, Business Development, Marketing, and Finance.
Fitch Affirms Allergan's IDR at 'A+'; Stable Outlook
Business Wire - Wed Mar 05, 10:16AM CST
Fitch Ratings has affirmed Allergan Inc.'s (Allergan) Issuer Default Rating (IDR) at 'A+'. A complete list of ratings affirmed is provided at the end of this release.
Global and Chinese Hyaluronic Acid Solution Industry Report 2014
M2 - Wed Mar 05, 2:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/g7vv9d/global_and) has announced the addition of the "Global and Chinese Hyaluronic Acid Solution Industry Report 2014" report to their offering. The Global and Chinese Hyaluronic Acid Solution Industry Report 2014 is a professional and in-depth study on the current state of the global hyaluronic acid solution industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. Hyaluronic acid solution market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Hyaluronic acid solution industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. A key feature of the report is its focus on key industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. Hyaluronic acid solution industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered - Hyaluronic Acid Solution Industry Overview - Hyaluronic Acid Solution International and China Market Analysis - Hyaluronic Acid Solution Development Environmental Analysis - Hyaluronic Acid Solution Development Policy and Plan - Hyaluronic Acid Solution Manufacturing Process and Cost Structure - 2009-2014 Hyaluronic Acid Solution Productions Supply Sales Demand Market Status and Forecast - Hyaluronic Acid Solution Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Hyaluronic Acid Solution Marketing Channels Analysis - 2014-2019 Hyaluronic Acid Solution Productions Supply Sales Demand Market Status and Forecast - Hyaluronic Acid Solution Industry Development Proposals - Hyaluronic Acid Solution New Project Investment Feasibility Analysis - Global and China Hyaluronic Acid Solution Industry Research Conclusions Companies Mentioned - Abbott Medical Optics - Allergan - Anika Therapeutics - Bausch Lomb - Bloomage Freda - CONTIPRO - Changzhou Institute of Material Medical - EME - Ferring Pharmaceuticals - Genzyme Biosurgery - Hangzhou Gallop - Hao Hai Healthcare - Henan Universe IOL - Hyaltech - Jingfeng - LG LIFE & SCIENCE - Lipo Chemicals - Medicis Aesthetics - Merz Pharmaceuticals - Novozymes - Q-Med - Seikagaku - Shiseido - Singclean Medical - Stanford Chemicals - Synvisc-One For more information visit http://www.researchandmarkets.com/research/g7vv9d/global_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Can Allergan's Growth Continue?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In the world of Big Pharma, growth is a precious commodity these days. Allergan is a noteworthy exception, though, as the company continues to see strong demand for cornerstone products like Botox an Restasis, as well as its facial aesthetics...
Boulder Brands Announces 2013 Fourth Quarter Results
Thomson Reuters ONE - Thu Feb 27, 7:31AM CST
Global Dry Eye Syndrome Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/xqq9pt/pharmapoint_dry) has announced the addition of the "PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022" report to their offering. Significant growth is expected in the DES market from 2012-2022. 2012 DES therapeutic sales to be approximately $1.6 billion across the 9 markets covered in this forecast: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By the end of the forecast period, sales will grow to $5.5 billion at a CAGR of 12.8%. The majority of the current DES drug sales are in the US although it is not the market with the greatest number of DES patients. DES is a relatively immature market and very few countries have a prescription eye drop on the market. The US has the top revenue-generating product, Restasis, approved for dry eye patients with total US drug sales for DES reaching almost $1 billion in 2012. The US will remain the most lucrative DES market over the forecast period despite the key patent expiration of Restasis and the approval of several late-stage drugs in competing markets Major drivers to the growth of the DES market over the forecast period will include: - The launch of novel pipeline drugs, which are predicted to generate strong uptake, as well as the growth and expansion of already launched products including Restasis, Diquas and Mucosta. - A global push for increased physician and patient awareness which will increase diagnosis and treatment rates - A rapidly growing elderly population to broadly expand the patient base. Major barriers to the growth of the DES market will include: - Patients self-medicating with artificial tears or home remedies and the severity of their DES worsening before seeking treatment - Patient compliance is typically very low for DES drugs - The increasingly crowded DES marketplace will make it more difficult for newer treatments to differentiate themselves from the established agents and achieve significant individual patient share. While the market is not currently crowded, the approval of several new treatments in the next 3 years will make it difficult for late-forecast entrants Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook Companies Mentioned - Allergan - Alcon (a wholly-owned subsidiary of Novartis AG) - Santen Pharmaceutical - Shire/SARcode Bioscience - Otsuka Holdings - Can-Fite Biopharma - Eyegate Pharma For more information visit http://www.researchandmarkets.com/research/xq...apoint_dry
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Research and Markets: Global Breast Implants Market to 2018 with Allergan, Mentor Worldwide & Sientra Dominating the Market
Business Wire - Wed Feb 26, 12:16PM CST
Research and Markets (http://www.researchandmarkets.com/research/jlzmgf/global_breast) has announced the addition of the "Global Breast Implants Market to 2018 with Allergan, Mentor Worldwide & Sientra Dominating the Market" report to their offering.
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 3:03PM CDT
It appears that not even geopolitical concerns and threats of a global growth slowdown can keep the broad-based S&P 500 from running to fresh all-time highs. For skeptics like me, that's an opportunity to see whether companies have earned their...
Survey Shows 3 out of 4 Women in the U.S. (ages 18-65) Think the Length, Thickness, or Color of Their Eyelashes is Inadequate(1)
PR Newswire - Thu Mar 13, 8:00AM CDT
According to a new U.S. survey conducted by Wakefield Research on behalf of Allergan, Inc., maker of BOTOX® Cosmetic (onabotulinumtoxinA), three out of four women (n = 500) have admitted to having concerns about their inadequate eyelashes. Of the women polled in the survey, 49 percent stated that they found the thickness or volume of their lashes inadequate.1 Additionally, 52 percent of women have noticed that their lashes have gotten thinner, shorter or lighter over time.1 And, 51 percent of those surveyed agreed that they either are using more mascara than they'd like, laying it on too thickly, or are afraid to have anyone see them without it.1
Beverly Hills Physicians is Proud to be Recognized with an Allergan Award
PR Newswire - Wed Mar 12, 7:25PM CDT
Throughout Southern California, Beverly Hills Physicians has long been the ideal option for cosmetic procedures like breast augmentation. With BHP's various facilities throughout the region (each approved by the American Association for Accreditation of Ambulatory Surgery, Inc.), their plastic surgery patients always know they're receiving the safest and most effective surgery. Further still, their experience, skill and dedication to cost-effective treatment means that every patient can achieve the same level of quality you'd expect to see among breast implants in Beverly Hills. That's why it is such a pleasure to announce that BHP was recently presented with the prestigious ALLERGAN PARTNER PRIVILEGES® (APP) Top 50 award - for the second year in a row!
Can Valeant Continue This Growth?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:00PM CDT
Canada's Valeant Pharmaceuticals is a good example of what can be done when a company chooses to go its own way and zig while others zag. In an industry that had becoming increasingly skittish about mergers and acquisitions as a growth driver,...
Equities Hitting New High: Allergan, Aetna, Ecolab, and BioDelivery Sciences Intl.
PR Newswire - Wed Mar 12, 11:17AM CDT
On Tuesday, March 11, 2014, the NASDAQ Composite finished at 4,307.19, down 0.63%. The Dow Jones Industrial Average closed the session at 16,351.25, down 0.41% and the S&P 500 ended the day at 1867.63, lower by 0.51%. The losses were broad based as nine out of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include Allergan Inc. (NYSE:AGN), Aetna Inc. (NYSE:AET), Ecolab Inc. (NYSE:ECL), and BioDelivery Sciences International Inc. (NASDAQ:BDSI). Free research on these four companies can be accessed at:
Kythera Regains ATX-101 from Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:39PM CDT
Kythera regained all rights to ATX-101 outside the U.S. and Canada from the HealthCare segment of Bayer.
Global Ophthalmic Drugs Market Report 2013-2018: Dry Eye, Anti-Glaucoma, Anti-Allergy/Inflammatory/Infective, Retinal Drugs
M2 - Mon Mar 10, 7:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w43p49/ophthalmic_drugs) has announced the addition of the "Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018" report to their offering. The global ophthalmic drugs market is rapidly growing due to increasing prevalence of eye disorders such as glaucoma, dry eye diseases and retinal diseases. Changing lifestyle, improved medical infrastructure, technological changes, increase in healthcare spending and aging population is also supporting the growth of the ophthalmic drugs market. Glaucoma is the largest drugs segment in global ophthalmic drugs market. Some of the major drugs for glaucoma treatment are Lumigan, Combigan, Xalatan, Ganfort and Saflutan. Diquas, Hyalein and Restasis are the major drugs for dry eye diseases. The retinal drugs market includes Ozurdex, Macugen, Visudyne and Lucentis. Patanol/Pataday, Tobradex, Vigamox and Bepreve are major ocular anti-inflammatory drugs. The ophthalmic drugs market covers prescription based drugs, OTC drugs and pipeline drugs. This report forecasts future potential of all these drug markets and analyses drivers and opportunities, restraints and challenges, market trends, Porter's forces, competitive landscape and company profiles of key players. The report categorizes the global ophthalmic drugs market based on major eye disorders, treatment drugs and geography. The treatment drugs market comprises treatment of major eye disorders such as glaucoma, dry eye drugs, retinal diseases and ocular inflammatory diseases. The market is further segmented on the basis of prescription based drugs, OTC drugs and pipeline drugs in different eye disorder areas. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Ophthalmic Drugs - Industry Analysis Chapter 4 Ophthalmic Drugs Market Trends Chapter 5 Porter's Five Force Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Ophthalmic Drugs Market - Treatment Drugs Chapter 8 Ophthalmic Drugs Market: Regional Analysis Chapter 9 Prescription vs. Over the Counter Drugs Chapter 10 Competitive Landscape Chapter 11 Company Profiles - Allergan - Merck - Novartis - Pfizer - Roche - Santen Pharmaceutical For more information visit http://www.researchandmarkets.com/research/w4...lmic_drugs
Allergan Up 39.3% Since SmarTrend Uptrend Call (AGN)
Comtex SmarTrend(R) - Fri Mar 07, 9:40AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on July 15th, 2013 at $91.28. In approximately 8 months, Allergan has returned 39.32% as of today's recent price of $127.17.
LatisseDoctor.com Reports on Allergan's Continued Work on Hair Loss Product Despite Delays
PRWeb - Fri Mar 07, 3:11AM CST
Allergan's move to take part in the massive hair loss market is the subject of the latest LatisseDoctor.com report. The current lineup of Allergan products include JUVÉDERM(R), BOTOX(R), VIVITE(R), SkinMedica(R), NATRELLE(R) breast implants and LATISSE(R). It is this last product that was the launching point for Allergan's attempt to enter the hair loss market reports LatisseDoctor.com. The active ingredient, bimatoprost was found to improve eyelash growth, and Allergan researchers are hoping it can do the same for hair.
Vansen Pharma Inc. appoints Ali Moghaddam to its Board of Advisors
PR Newswire - Thu Mar 06, 9:47AM CST
Vansen Pharma Inc. [OTCQB: VNSN] is pleased to announce the appointment of Mr. Ali Moghaddam to its Board of Advisors. Mr. Moghaddam is an accomplished pharmaceutical executive with over 25 years of experience in both Canada and the U.S., having played a transformational role with companies such as Bristol-Myers Squibb Canada, Linson Pharma Inc. (generic business unit of BMS), Allergan Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group). He brings a proven track record of hands-on leadership within the life sciences field, in the areas of Product Life Cycle Management, Sales, Business Development, Marketing, and Finance.
Fitch Affirms Allergan's IDR at 'A+'; Stable Outlook
Business Wire - Wed Mar 05, 10:16AM CST
Fitch Ratings has affirmed Allergan Inc.'s (Allergan) Issuer Default Rating (IDR) at 'A+'. A complete list of ratings affirmed is provided at the end of this release.
Global and Chinese Hyaluronic Acid Solution Industry Report 2014
M2 - Wed Mar 05, 2:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/g7vv9d/global_and) has announced the addition of the "Global and Chinese Hyaluronic Acid Solution Industry Report 2014" report to their offering. The Global and Chinese Hyaluronic Acid Solution Industry Report 2014 is a professional and in-depth study on the current state of the global hyaluronic acid solution industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. Hyaluronic acid solution market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Hyaluronic acid solution industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. A key feature of the report is its focus on key industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. Hyaluronic acid solution industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered - Hyaluronic Acid Solution Industry Overview - Hyaluronic Acid Solution International and China Market Analysis - Hyaluronic Acid Solution Development Environmental Analysis - Hyaluronic Acid Solution Development Policy and Plan - Hyaluronic Acid Solution Manufacturing Process and Cost Structure - 2009-2014 Hyaluronic Acid Solution Productions Supply Sales Demand Market Status and Forecast - Hyaluronic Acid Solution Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Hyaluronic Acid Solution Marketing Channels Analysis - 2014-2019 Hyaluronic Acid Solution Productions Supply Sales Demand Market Status and Forecast - Hyaluronic Acid Solution Industry Development Proposals - Hyaluronic Acid Solution New Project Investment Feasibility Analysis - Global and China Hyaluronic Acid Solution Industry Research Conclusions Companies Mentioned - Abbott Medical Optics - Allergan - Anika Therapeutics - Bausch Lomb - Bloomage Freda - CONTIPRO - Changzhou Institute of Material Medical - EME - Ferring Pharmaceuticals - Genzyme Biosurgery - Hangzhou Gallop - Hao Hai Healthcare - Henan Universe IOL - Hyaltech - Jingfeng - LG LIFE & SCIENCE - Lipo Chemicals - Medicis Aesthetics - Merz Pharmaceuticals - Novozymes - Q-Med - Seikagaku - Shiseido - Singclean Medical - Stanford Chemicals - Synvisc-One For more information visit http://www.researchandmarkets.com/research/g7vv9d/global_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Can Allergan's Growth Continue?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In the world of Big Pharma, growth is a precious commodity these days. Allergan is a noteworthy exception, though, as the company continues to see strong demand for cornerstone products like Botox an Restasis, as well as its facial aesthetics...
Boulder Brands Announces 2013 Fourth Quarter Results
Thomson Reuters ONE - Thu Feb 27, 7:31AM CST
Global Dry Eye Syndrome Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/xqq9pt/pharmapoint_dry) has announced the addition of the "PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022" report to their offering. Significant growth is expected in the DES market from 2012-2022. 2012 DES therapeutic sales to be approximately $1.6 billion across the 9 markets covered in this forecast: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By the end of the forecast period, sales will grow to $5.5 billion at a CAGR of 12.8%. The majority of the current DES drug sales are in the US although it is not the market with the greatest number of DES patients. DES is a relatively immature market and very few countries have a prescription eye drop on the market. The US has the top revenue-generating product, Restasis, approved for dry eye patients with total US drug sales for DES reaching almost $1 billion in 2012. The US will remain the most lucrative DES market over the forecast period despite the key patent expiration of Restasis and the approval of several late-stage drugs in competing markets Major drivers to the growth of the DES market over the forecast period will include: - The launch of novel pipeline drugs, which are predicted to generate strong uptake, as well as the growth and expansion of already launched products including Restasis, Diquas and Mucosta. - A global push for increased physician and patient awareness which will increase diagnosis and treatment rates - A rapidly growing elderly population to broadly expand the patient base. Major barriers to the growth of the DES market will include: - Patients self-medicating with artificial tears or home remedies and the severity of their DES worsening before seeking treatment - Patient compliance is typically very low for DES drugs - The increasingly crowded DES marketplace will make it more difficult for newer treatments to differentiate themselves from the established agents and achieve significant individual patient share. While the market is not currently crowded, the approval of several new treatments in the next 3 years will make it difficult for late-forecast entrants Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook Companies Mentioned - Allergan - Alcon (a wholly-owned subsidiary of Novartis AG) - Santen Pharmaceutical - Shire/SARcode Bioscience - Otsuka Holdings - Can-Fite Biopharma - Eyegate Pharma For more information visit http://www.researchandmarkets.com/research/xq...apoint_dry
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Research and Markets: Global Breast Implants Market to 2018 with Allergan, Mentor Worldwide & Sientra Dominating the Market
Business Wire - Wed Feb 26, 12:16PM CST
Research and Markets (http://www.researchandmarkets.com/research/jlzmgf/global_breast) has announced the addition of the "Global Breast Implants Market to 2018 with Allergan, Mentor Worldwide & Sientra Dominating the Market" report to their offering.
